Gerresheimer AG (ETR:GXI – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as €74.00 ($77.89) and last traded at €75.80 ($79.79), with a volume of 98092 shares. The stock had previously closed at €76.80 ($80.84).
Gerresheimer Stock Performance
The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of 22.50, a P/E/G ratio of 0.82 and a beta of 0.94. The company has a quick ratio of 0.40, a current ratio of 0.87 and a debt-to-equity ratio of 79.36. The company has a 50-day moving average price of €80.48 and a 200-day moving average price of €93.24.
About Gerresheimer
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services.
Further Reading
- Five stocks we like better than Gerresheimer
- What Is WallStreetBets and What Stocks Are They Targeting?
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- What Do S&P 500 Stocks Tell Investors About the Market?
- Netflix Is On Track To Hit $1,000 By Christmas
- How Can Investors Benefit From After-Hours Trading
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.